What Happened
A publicly traded transportation and logistics company based in Illinois is now facing a shareholder derivative lawsuit tied to problems with its financial reporting, according to a court filing reported by Courthouse News. Earlier in 2026, the company reportedly told investors that its financial statements covering the first three quarters of 2025 should no longer be relied on because certain operating costs had not been reported correctly. The company later disclosed that its full-year reports for 2023 and 2024 were also allegedly misstated in material ways.
According to the reporting, the news hit the company's stock hard. Shares reportedly fell about 18% the day after the initial disclosure and dropped another 13% when the older restatements came to light — roughly a 31% decline overall.
A shareholder has now filed a 58-page derivative complaint against the company, its board of directors, and certain executive officers. The suit reportedly alleges breach of fiduciary duty, gross mismanagement, and waste of corporate assets. It also alleges violations of Section 14(a) of the Securities Exchange Act of 1934, which governs proxy solicitations. The filing follows a separate securities class action that was reportedly brought about a month earlier. The company has not publicly responded to requests for comment, according to the source.
None of the allegations have been proven in court. The lawsuit represents one side's account.
Why It Matters Legally
This story sits at the intersection of several important corners of business and corporate law: securities regulation, corporate governance, and fiduciary duty. When a public company restates its financials — meaning it formally tells investors that earlier reports were wrong — it can set off a chain reaction of legal activity.
Two main types of lawsuits typically follow a significant restatement:
- Securities class actions, generally brought on behalf of investors who bought shares during the period when the misstatements were allegedly in effect. These focus on losses tied to a stock drop.
- Shareholder derivative lawsuits, like the one described here, in which a shareholder sues the company's officers and directors on behalf of the company itself. The theory is that leadership's alleged failures harmed the corporation, and any recovery generally flows back to the company.
Who Could Be Affected
Restatement disputes touch a surprisingly wide group of people. In general, categories who might have a stake in cases like this include:
- Long-term shareholders who held stock through the period of alleged misstatements and saw their investment value drop.
- Retirement savers and pension funds whose portfolios include the company's shares, sometimes without the individual investor even realizing it.
- Current and former officers and directors, who may face personal claims for allegedly failing their oversight duties.
- Auditors and accounting professionals, whose work may be scrutinized as part of the review of internal controls.
- Employees whose retirement plans hold company stock, and who could be affected by any downstream financial or reputational fallout.
How Cases Like This Generally Work
Derivative lawsuits and securities class actions each follow their own general playbook, but there are some common threads.
Early stages. In a derivative case, the plaintiff typically must show either that they made a formal demand on the board to take action — and the board refused — or that making such a demand would have been futile because the directors themselves are allegedly conflicted. Courts often decide this threshold issue before the merits.
What the evidence looks like. Lawyers on both sides generally focus on internal documents: board minutes, audit committee reports, communications with outside auditors, whistleblower complaints, and drafts of financial statements. The core questions typically include: What did leadership know? When did they know it? What steps did they take (or fail to take) once red flags appeared?
Internal controls. A recurring theme in accounting-related cases is whether the company had adequate internal controls over financial reporting, as required under federal securities laws. Weak or ignored controls can support arguments that directors failed their oversight duties under state corporate law — often called Caremark claims, named after a well-known Delaware decision.
Timelines. These cases generally move slowly. Motion practice — especially motions to dismiss — can take a year or more. If a case survives dismissal, discovery may add another year or two. Many derivative suits ultimately resolve through settlements that include corporate governance reforms (like new board committees, revised policies, or leadership changes) rather than large cash payments to individual shareholders.
Parallel proceedings. It's common for the U.S. Securities and Exchange Commission to open its own investigation when a public company restates its financials. Criminal referrals are rarer but not unheard of when intentional misconduct is alleged. Insurance carriers that provide directors and officers (D&O) coverage may also become involved behind the scenes.
What to Watch Next
Readers following stories like this can generally expect several developments over the coming months:
- Consolidation of lawsuits. Multiple derivative suits, if filed by different shareholders, are often combined. The derivative case and the earlier-filed securities class action may proceed on parallel tracks.
- Motions to dismiss. Defendants in these cases typically challenge the complaint's sufficiency early. Rulings on those motions can significantly shape the case.
- SEC activity. Any public statements or enforcement filings from the SEC would likely be noteworthy.
- Internal reviews. The company may disclose the findings of any independent investigation into the accounting issues, along with the total dollar impact of the restatements.
- Governance changes. Watch for announcements about leadership changes, new audit committee members, or updated internal control procedures.
- Settlement signals. In some cases, settlements are announced before trial, sometimes bundled with policy reforms designed to prevent a repeat.